Neurocrine Bioscienc (NBIX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Sales | 2,355,300 | 1,887,100 | 1,488,700 | 1,133,500 | 1,045,900 |
| Cost of Goods | 34,000 | 39,700 | 23,200 | 14,300 | 10,100 |
| Gross Profit | 2,321,300 | 1,847,400 | 1,465,500 | 1,119,200 | 1,035,800 |
| Operating Expenses | 1,750,800 | 1,597,200 | 1,216,700 | 1,017,000 | 872,900 |
| Operating Income | 570,500 | 250,900 | 249,000 | 102,500 | 163,000 |
| Interest Expense | 0 | 0 | 0 | 25,800 | 32,800 |
| Other Income | -84,500 | 81,200 | -35,100 | 24,700 | -23,500 |
| Pre-tax Income | 486,000 | 332,100 | 213,900 | 101,400 | 106,700 |
| Income Tax | 144,700 | 82,400 | 59,400 | 11,800 | -300,600 |
| Net Income Continuous | 341,300 | 249,700 | 154,500 | 89,600 | 407,300 |
| Net Income | $341,300 | $249,700 | $154,500 | $89,600 | $407,300 |
| EPS Basic Total Ops | 3.40 | 2.56 | 1.61 | 0.95 | 4.38 |
| EPS Basic Continuous Ops | 3.40 | 2.56 | 1.61 | 0.95 | 4.37 |
| EPS Diluted Total Ops | 3.29 | 2.47 | 1.56 | 0.92 | 4.16 |
| EPS Diluted Continuous Ops | 3.29 | 2.47 | 1.56 | 0.92 | 4.16 |
| EPS Diluted Before Non-Recurring Items | 3.29 | 2.47 | 1.56 | 0.92 | 4.16 |
| EBITDA(a) | $571,400 | $253,900 | $268,300 | $138,100 | $193,000 |